

**Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing both
Kinase-Dependent and Kinase-Independent Functions of the Receptor**

Yuesheng Zhang

Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth
University

Massey Comprehensive Cancer Center, Virginia Commonwealth University

Running Title:

Targeting EGFR for Cancer Treatment

Corresponding Author: Yuesheng Zhang, MD, PhD
Virginia Commonwealth University
School of Medicine
Department of Pharmacology and Toxicology
Massey Comprehensive Cancer Center
401 College Street
Richmond, VA 23298
Phone 804-628-8679
Fax 804-827-1548
Email: yuesheng.zhang@vcuhealth.org

Text pages: 66
Tables: 2
Figures: 2
References: 200
Abstracts: 249 words

Non-Standard Abbreviations:

ADCC	Antibody-dependent cellular cytotoxicity
AREG	Amphiregulin
ATM	Ataxia-telangiectasia mutated protein kinase
BTC	Betacellulin
CME	Clathrin-mediated endocytosis
CRC	Colorectal cancer
DNAPK	DNA-dependent protein kinase
ECD	Extracellular domain
EMT	Epithelial-mesenchymal transition
EPGN	Epigen
EREG	Epiregulin
Exon19del	Exon 19 deletion

FAS	Fatty acid synthase
FGFR	Fibroblast growth factor receptor
GBM	Glioblastoma multiforme
HB-EGF	Heparin-binding EGF-like growth factor
HNSCC	Head and neck squamous cell carcinoma
HT	Hydroxytyrosol
IGF1R	Insulin like growth factor 1 receptor
JAK2	Janus tyrosine kinase 2
LAPTM4B	Lysosomal-associated transmembrane protein 4B
MERTK	MER receptor tyrosine kinase
NCE	Non-clathrin endocytosis
NSCLC	Non-small cell lung cancer
PCNA	Proliferation cell nuclear antigen
PDGFR	Platelet derived growth factor receptor
PEPD	Peptidase D
PROTAC	Proteolysis targeting chimera
PUMA	p53 upregulated modulator of apoptosis
SGLT1	Sodium/glucose cotransporter 1
TKI	Tyrosine kinase inhibitor
VHL	von Hippel-Lindau

ABSTRACT

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent oncogenic activities in a variety of human cancers. A large number of EGFR inhibitors have been developed for cancer treatment, including monoclonal antibodies, tyrosine kinase inhibitors, and a vaccine. The EGFR inhibitors are aimed at inhibiting the activation or the activity of EGFR tyrosine kinase. However, these agents have shown efficacy only in a few types of cancers. Drug resistance, both intrinsic and acquired, is common even in cancers where the inhibitors have shown efficacy. The drug resistance mechanism is complex and not fully known. The key vulnerability of cancer cells that are resistant to EGFR inhibitors has not been identified. Nevertheless, it has been increasingly recognized in recent years that EGFR also possesses kinase-independent oncogenic functions and that these noncanonical functions may play a crucial role in cancer resistance to EGFR inhibitors. In this review, both kinase-dependent and -independent activities of EGFR are discussed. Also discussed are the mechanisms of actions and therapeutic activities of clinically used EGFR inhibitors, and sustained EGFR overexpression and EGFR interaction with other receptor tyrosine kinases to counter the EGFR inhibitors. Moreover, this review discusses emerging experimental therapeutics that have shown potential of overcoming the limitation of the current EGFR inhibitors in preclinical studies. The findings underscore the importance and feasibility of targeting both kinase-dependent and -independent functions of EGFR, to enhance therapeutic efficacy and minimize drug resistance.

SIGNIFICANCE STATEMENT

EGFR is a major oncogenic driver and therapeutic target, but cancer resistance to current EGFR inhibitors remains a significant unmet clinical problem. Here, I review the cancer biology of EGFR as well as the mechanisms of actions and the therapeutic efficacies of current and emerging EGFR inhibitors. The findings could potentially lead to development of more effective treatments for EGFR-positive cancers.

TABLE OF CONTENT

- I. INTRODUCTION**
 - 1. The HER Family Receptor Tyrosine Kinases**
 - 2. EGFR Overexpression and Mutation in Cancer**
 - 3. Clinically Used EGFR Inhibitors**
 - 4. Clinical Activities of EGFR Inhibitors**

- II. KINASE-DEPENDENT ACTIVITIES OF EGFR**
 - 1. Ligand-Dependent and -Independent Activation of EGFR Kinase**
 - 2. EGFR Internalization and Trafficking**
 - 3. EGFR Functions in Noncanonical Locations**

- III. KINASE-INDEPENDENT ACTIVITIES OF EGFR**

- IV. MECHANISMS OF ACTIONS AND THERAPEUTIC ACTIVITIES OF CLINICALLY USED EGFR INHIBITORS**
 - 1. TKIs**
 - 2. mAbs**
 - 3. CIMAvax**

- V. SUSTAINED EGFR OVEREXPRESSION AND EGFR CROSSTALK WITH OTHER RTKS TO COUNTER EGFR INHIBITORS**

1. Lack of Downregulation of EGFR and Its Mutants Confers Resistance to EGFR Inhibitors

2. Heterodimerization of EGFR and Its Mutants with Other RTKs Confers Resistance to EGFR Inhibitors

VI. EMERGING EGFR DEGRADERS AND THEIR THERAPEUTIC ACTIVITIES

1. PROTACs

2. Non-PROTAC Small Molecules

3. Antibody Combinations

4. Non-Antibody Proteins

VII. CONCLUDING REMARKS

VIII. ACKNOWLEDGMENTS

IX. DATA AVAILABILITY

X. AUTHORSHIP CONTRIBUTION

XI. REFERENCES

XII. FOOTNOTES

XIII. TABLES

XIV. FIGURE LEGENDS

I. INTRODUCTION

1. The HER Family Receptor Tyrosine Kinases

EGFR, also known as ErbB1 or HER1, which was discovered by Cohen and coworkers in 1978 (Carpenter et al., 1978), is a member of the HER family of four closely related RTKs. The other HER family members include HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). The HER receptors are single-pass transmembrane proteins, composed of an extracellular domain (ECD), a transmembrane domain, an intracellular tyrosine kinase domain, and a C-terminal tail. Upon ligand binding to the ECD of the RTKs or their own overexpression, the receptors undergo homo- or hetero-dimerization, which results in tyrosine kinase activation and auto- or trans-phosphorylation of tyrosine residues in the C-terminal tail. The phospho-tyrosine sites recruit adaptor proteins, signaling proteins, and regulatory proteins to activate various growth signaling pathways, such as the RAS/RAF/MEK/ERK pathway, and the PI3K/AKT/mTOR pathway (Figure 1) (Wee and Wang, 2017). However, HER3 kinase is almost totally inactive due to non-conservative substitution of several amino acids in its kinase domain but exerts potent oncogenic activity by relying on trans-phosphorylation by another RTK with which it heterodimerizes (Beji et al., 2012; Lee et al., 2009; Lyu et al., 2018). EGFR can also function without requiring its kinase activity, as described later. The HER RTKs play important roles in various developmental and physiological processes but excessive activity resulting from overexpression or activating mutation drives cancer development and progression (Roskoski, 2014; Sibia et al., 2007).

2. EGFR Overexpression and Mutation in Cancer

EGFR is overexpressed in a variety of human cancers. High tumor EGFR expression is linked to poor prognosis in bladder cancer (Neal et al., 1990), breast cancer (Lee et al., 2015b), cervical cancer (Tian et al., 2016), esophageal cancer (Jiang et al., 2015), head and neck cancer (Chung et al., 2011), ovarian cancer (Psyrrri et al., 2005), and stomach cancer (Galizia et al., 2007). EGFR is also overexpressed in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and glioblastoma multiforme (GBM), but the prognostic significance of EGFR overexpression is not observed in NSCLC and GBM (Heimberger et al., 2005; Hirsch et al., 2003) and is controversial in CRC (Hong et al., 2013; Rego et al., 2010; Spano et al., 2005). The mechanism of EGFR overexpression is not fully understood. EGFR overexpression results mainly from gene amplification in GBM (Viana-Pereira et al., 2008), but in CRC and NSCLC, *EGFR* is amplified in about 10-16% of CRC cases and about 10% of NSCLC cases, while EGFR is overexpressed in about 60% of the cases in both diseases (Hirsch et al., 2003; Kato et al., 2019; Shia et al., 2005; Spano et al., 2005). Gene amplification is not the main driver of EGFR overexpression in head and neck squamous cell carcinoma (HNSCC) as well (Bei et al., 2004; Maiti et al., 2013). Several studies show that EGFR expression may be induced by its own ligand through increasing protein synthesis (Clark et al., 1985; Kudlow et al., 1986; Yoshida et al., 1989). Activating EGFR mutation is common only in NSCLC and GBM. EGFR is mutated in its kinase domain in NSCLC in 10-20% of the cases in North America and Europe and 40-64% of the cases in Asia (Midha et al., 2015). In contrast, EGFR is activated by point or deletion mutations in its ECD in GBM (An et al., 2018). EGFRvIII, an in-frame deletion of exons 2-7 removing 267 amino acids, is the most common EGFR mutant in GBM and occurs in 20-30% of the cases (Gan et al., 2013; Heimberger et al., 2005).

3. Clinically Used EGFR Inhibitors

Reflecting the critical importance of EGFR as a therapeutic target in cancer, a total of 20 direct EGFR inhibitors have been developed over the past two decades, which include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) (Table 1). Since the approval of gefitinib as the first EGFR TKI in 2003, 15 additional EGFR TKIs have been developed. The EGFR TKIs are either reversible or irreversible inhibitors and are approved either in the US (gefitinib, erlotinib, lapatinib, afatinib, brigatinib, dacomitinib, mobocertinib, neratinib, osimertinib, pyrotinib, and vandetanib) or outside the US (icotinib, almonertinib, simotinib, lazertinib, and olmutinib). The EGFR TKIs were recently reviewed (Abourehab et al., 2021), except for mobocertinib (Gonzalvez et al., 2021; Han et al., 2021a) and lazertinib (Dhillon, 2021; Heppner et al., 2022), both of which were approved in 2021. Some of the EGFR TKIs are also inhibitors of other RTKs. Lapatinib also inhibits HER2 and is known as a dual EGFR/HER2 TKI. Afatinib, dacomitinib, neratinib and pyrotinib also inhibit HER2 and HER4 and are known as pan-HER TKIs. Brigatinib and vandetanib are multikinase inhibitors. Brigatinib also inhibits anaplastic lymphoma kinase, fms like tyrosine kinase 3, and ROS1. Vandetanib also inhibits vascular endothelial growth factor receptor-1/2/3 and RET. Since the approval of cetuximab as the first EGFR mAb in 2004, three additional EGFR mAbs have been developed. Three EGFR mAbs are approved in the US, including cetuximab, panitumumab, and necitumumab, and another, nimotuzumab, is approved outside the US (Cai et al., 2020; Ramakrishnan et al., 2009; Yao et al., 2018). In addition to the EGFR TKIs and mAbs, a vaccine known as CIMAvax was developed in Cuba and entered the first clinical trial in 1998 there (Gonzalez et al., 1998). CIMAvax inhibits EGFR activation by generating antibodies against circulating epidermal growth factor (EGF), one of the EGFR ligands (Rodriguez et al., 2010).

4. Clinical Activities of EGFR Inhibitors

Although EGFR is implicated as an oncogenic driver in a variety of human cancers as described before, the EGFR inhibitors have shown clinical efficacy only in a few types of cancers. The EGFR TKIs are approved only for treating NSCLC harboring activating EGFR mutation, except for lapatinib, neratinib, pyrotinib, and vandetanib. Lapatinib, neratinib and pyrotinib, which also inhibit HER2, are approved for treating HER2-positive breast cancer (Table 1). Vandetanib, which is a multikinase inhibitor, is approved for treating medullary thyroid cancer (Table 1). The EGFR mAbs are approved for treating CRC, HNSCC, or squamous cell lung carcinoma (squamous NSCLC) depending on the mAb, except for nimotuzumab which is approved outside the US for treating HNSCC, glioma, and nasopharyngeal carcinoma (Table 1). CIMAvax has not been approved in the US, but a phase 1 trial in the US showed that CIMAvax is safe in NSCLC patients (Evans et al., 2022). The US Food and Drug Administration denied approval of poziotinib (an EGFR TKI) for patients with NSCLC in 2022 on the ground that benefit does not outweigh risk (<http://bit.ly/3Vy8TkB>). Even in cancers where the drugs show clinical efficacy, intrinsic and acquired drug resistance is common, as discussed in section IV. Cancer resistance to EGFR inhibitors and the complex mechanisms of resistance have been the subjects of numerous reviews, some of which are cited here (Bertotti and Sassi, 2015; Leonetti et al., 2019; Pan and Magge, 2020; Parseghian et al., 2019; Westover et al., 2018). However, translating the knowledge of drug resistance mechanism to benefit patients has been very challenging. For example, activating KRAS mutation was found to confer resistance to EGFR inhibitors in NSCLC, and KRAS^{G12C} is the most common activating KRAS mutant in NSCLC (Kempf et al., 2016). However, in a phase 3 clinical trial, sotorasib, which inhibits KRAS^{G12C}, achieved median

progression-free survival 5.6 months in NSCLC patients whose tumors harbor this mutation, compared to docetaxel which targets microtubule and achieved median progression-free survival 4.5 month (de Langen et al., 2023). KRAS mutation also renders CRC resistant to EGFR mAbs, but sotorasib achieves objective response rate of only 7-10% in patients whose tumors harbor KRAS^{G12C} (Fakih et al., 2022; Hong et al., 2020). Even in patients whose tumors respond to sotorasib, response is not durable. The key vulnerability of therapy-resistant cancer cells remains unknown. The EGFR inhibitors inhibit the activation or activity of EGFR tyrosine kinase but not its kinase-independent oncogenic functions.

II. KINASE-DEPENDENT ACTIVITIES OF EGFR

1. Ligand-Dependent and -Independent Activation of EGFR Kinase

EGFR and its family members are best known for its kinase-dependent signaling from cell surface membrane. EGFR is stimulated by seven ligands with varying affinity (Olayioye et al., 2000; Singh et al., 2016). Four ligands are specific to EGFR, including EGF, transforming growth factor α (TGF α), amphiregulin (AREG), and epigen (EPGN). Three ligands bind to both EGFR and HER4, including heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EREG), and betacellulin (BTC). Ligand binding to the ECD of EGFR induces homo- and hetero-dimerization, activation of tyrosine kinase, and phosphorylation of tyrosine residues in the C-terminal tail. These phosphotyrosine sites act as docking locations for a variety of proteins, which trigger cascades of downstream growth signaling (Figure 1). In-depth molecular details of the activation of EGFR tyrosine kinase may be found in a recent review (Wee and Wang, 2017). EGFR may also form inactive dimer before ligand binding and kinase activation (Hajdu et al.,

2020; Yu et al., 2002). In fact, all HER family receptors may pre-form homo- and hetero-dimers on the cell surface (Tao and Maruyama, 2008). Cancer cells may also overexpress EGFR ligands to enhance its oncogenic signaling. In a study of stomach cancer, high expression of EGF, BTC, EREG, HB-EGFR, TGF α , and AREG was detected in 8%, 12%, 24%, 29%, 31%, and 48% of the cases, respectively, and there are considerable positive correlations among the ligands (Byeon et al., 2017). Hobor et al. showed that CRC cells resistant to EGFR mAbs secret TGF α and AREG to protect surrounding cells from EGFR blockade (Hobor et al., 2014). In addition, EGFR kinase may be activated without ligand binding. EGFR becomes tyrosine phosphorylated and initiates signaling when overexpressed, while subsequent ligand binding may induce EGFR conformation change and a shift of downstream signaling (Chakraborty et al., 2014). Palmitoylation of EGFR by intracellular fatty acid synthase (FAS) also leads to EGFR dimerization and kinase activation in the absence of ligand (Bollu et al., 2015). Persistent signaling by mutated EGFR in TKI-resistant cancer cells was reported to rely on EGFR palmitoylation (Ali et al., 2018). It was also shown that Janus tyrosine kinase 2 (JAK2) and SRC activate EGFR by phosphorylating its tyrosine residues (Biscardi et al., 1999; Yamauchi et al., 1997). Most notably, constitutive activation of EGFR kinase results from activating gene mutation, which is common in NSCLC and GBM as mentioned before. However, while EGFR overexpression and mutation are known to drive oncogenesis and confer therapy resistance, it is not known to what extent EGFR activation by FAS, JAK2 or SRC may contribute to these activities.

2. EGFR Internalization and Trafficking

Activated EGFR may be internalized, which may be recycled back to cell membrane or delivered to lysosome (Sigismund et al., 2008), mitochondria (Demory et al., 2009), nucleus (Wang et al., 2010), or exosome (Sanderson et al., 2008) (Figure 1). The mechanisms of EGFR internalization and trafficking are complex and are not fully known. Sortilin, a membrane glycoprotein, was shown to bind to EGFR (Figure 2) and limit its signaling by promoting its internalization in lung cancer (Al-Akhrass et al., 2017). In NSCLC patients, sortilin expression decreases with increase in pathologic grade and strongly correlates with survival, especially in patients with high EGFR expression (Al-Akhrass et al., 2017). EGFR is internalized by clathrin-mediated endocytosis (CME) or non-clathrin endocytosis (NCE) as a function of ligand dose and EGFR ubiquitination, with high ligand dose and lack of ubiquitination favoring CME (Sigismund et al., 2013; Sigismund et al., 2005). p38 kinase-mediated phosphorylation of the C-terminal tail of unliganded EGFR, which may result from minimal EGFR activation by low level of ligand, also induces EGFR internalization via CME (Tanaka et al., 2018). CME-internalized EGFR is predominantly recycled back to cell membrane, whereas NCE commits EGFR to degradation in lysosomes (Sigismund et al., 2008). There is evidence that CME contributes to cancer resistance to EGFR TKI (Kim et al., 2021; Menard et al., 2018). Additional information is available in a comprehensive review (Caldieri et al., 2018), regarding the mechanism of EGFR endocytosis, postendocytic trafficking, importance of endocytosis in controlling EGFR signaling and function, and how cancer cells evade endocytic control of EGFR signaling to gain growth advantage. Interestingly, genetic and pharmacologic dynamin-mediated inhibition of EGFR endocytosis was shown to improve natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and reverse tumor cell resistance to cetuximab (Chew et al., 2020).

3. EGFR Functions in Noncanonical Locations

While recycling EGFR back to cell membrane helps sustain its signaling, EGFR trafficked to other locations may also exert oncogenic activities. Nuclear EGFR has been shown to promote cancer growth, progression, and therapy resistance via multiple mechanisms (Brand et al., 2011; Lee et al., 2015a). Nuclear EGFR functions as a transcriptional co-activator for oncogenes (e.g., cyclin D1 and cyclooxygenase-2), and as a protein kinase that phosphorylates, stabilizes and activates proliferation cell nuclear antigen (PCNA) and ataxia-telangiectasia mutated (ATM) protein kinase. It also physically interacts with DNA-dependent protein kinase (DNAPK) to promote DNA repair. EGFR may also contribute to cancer growth, progression and therapy resistance by binding to p53 upregulated modulator of apoptosis (PUMA) to prevent its accumulation in mitochondria and by translocating to mitochondria to induce mitochondrial fission and distribution (Che et al., 2015; Zhu et al., 2010). EGFR shed from cancer cells and carried in exosomes was shown to induce angiogenic signaling in endothelial cells (Al-Nedawi et al., 2009). Some of the EGFR functions in the non-canonical locations may be kinase-independent, such as its transcriptional functions, and its regulation of DNAPK and PUMA. Even if the EGFR functions are kinase-mediated in these locations, it is not known if any clinically used EGFR inhibitor has an effect on such functions.

III. KINASE-INDEPENDENT ACTIVITIES OF EGFR

EGFR knockout either is embryonically lethal or causes the newborn to die within 3 weeks, depending on the genetic background (Sibilia and Wagner, 1995; Threadgill et al., 1995). However, mice carrying a point mutation in the EGFR kinase domain (V743G) which reduces its tyrosine kinase activity by 80-95% are normal except for some abnormalities in the skin and eye

(Luetteke et al., 1994). A kinase inactive EGFR mutant (D813A) stimulates MAP kinase activity and DNA synthesis in response to EGF in cultured cells (Coker et al., 1994). Another kinase inactive EGFR mutant (K721R) prevents apoptosis induced by interleukin 3 withdrawal (Ewald et al., 2003). Kinase-inactive EGFR mutants also were detected in human NSCLC tumors (Kancha et al., 2009). There is evidence that EGFR exerts its kinase-independent functions in several cellular locations, including cell membrane, endosome, mitochondria, and nucleus. On cell membrane, loss of EGFR expression, but not inhibition of its kinase activity, results in autophagic cancer cell death (Weihua et al., 2008). EGFR, independent of its kinase activity, may prevent cell death in part by directly interacting with sodium/glucose cotransporter 1 (SGLT1) (Figure 2), which stabilizes SGLT1 and maintains intracellular glucose (Weihua et al., 2008). Independent of its kinase activity, EGFR also increases cancer cell invasion by directly interacting with and promoting the expression and function of the cysteine-glutamate transporter xCT (Figure 2) (Tsuchihashi et al., 2016). xCT is a major cell membrane antiporter that mediates cellular uptake of cysteine and has been implicated in tumor growth, progression and drug resistance (Liu et al., 2020). At the endosome, EGFR interacts with the lysosomal-associated transmembrane protein 4B (LAPTM4B) (Figure 2), independent of its kinase function, to stimulate autophagy for survival under serum starvation or metabolic stress (Tan et al., 2015). Notably, autophagy may have opposing and context-dependent effects on cancer cell growth and survival (Yun and Lee, 2018). Mitochondrial EGFR was shown to induce mitochondria fission independent of its kinase activity (Che et al., 2015). Nuclear EGFR may also exert its transcriptional activity independent at least partly of its kinase activity. Kinase-deficient EGFR was shown to transcriptionally activate *FOS* gene expression (Eldredge et al., 1994). In addition, as described in section V, EGFR may function without requiring its kinase activity by forming

heterodimeric signaling units with other RTKs. Additional information about the kinase-independent activities of EGFR may be found in previous reviews (Lee et al., 2015a; Sigismund et al., 2018; Tan et al., 2016; Thomas and Weihua, 2019). Collectively, while the literature on the kinase-independent functions of EGFR is much less than that on the kinase-dependent functions of EGFR, there is convincing evidence that EGFR exerts significant kinase-independent functions.

IV. MECHANISMS OF ACTIONS AND THERAPEUTIC ACTIVITIES OF CLINICALLY USED EGFR INHIBITORS

1. TKIs

Sixteen EGFR TKIs have been approved for clinical use (Table 1). Some of the EGFR TKIs are reversible inhibitors, including brigatinib, elotinib, gefitinib, icotinib, lapatinib, simotinib, and vandetanib. Others are irreversible inhibitors, including afatinib, almonertinib, dacomitinib, lazertinib, mobocertinib, neratinib, olmutinib, osimertinib, and pyrotinib. The reversible inhibitors function by competing with ATP binding to the kinase domain, whereas the irreversible inhibitors act by covalently binding to a cysteine residue (Cys797) in the kinase domain (Hossam et al., 2016). The TKIs differ in target specificity with regard to wild type (WT) EGFR vs its mutants. For example, gefitinib and erlotinib are as potent against WT EGFR as against sensitive mutants, including exon 19 deletion (Exon19del), L858R, and L861Q (Kitagawa et al., 2013). Osimertinib, however, is 7.5-300 times more potent against EGFR mutants, including L858R/T790M, Exon19del/T790M, Exon19del, L858R, and L861Q, than WT EGFR, with IC₅₀ values of 0.1, 0.9, 0.93, 1, 4 and 30 nM, respectively (Han et al., 2021b). The EGFR TKIs have been approved only for treating NSCLC harboring mutant EGFR, except

for several TKIs that also target other RTKs and are used to treat HER2-positive breast cancer or medullary thyroid cancer (Table 1). While NSCLC patients whose tumors harbor EGFR mutation frequently derive clinical benefit from EGFR TKI, resistance invariably develops, typically after a median of 9-15 months of treatment (Leonetti et al., 2019; Westover et al., 2018). Also, 20-30% of the patients are intrinsically resistant to the drugs, i.e., no response or responding for less than 3 months (Santoni-Rugiu et al., 2019; Wang et al., 2016). The drug resistance mechanisms are complex and not fully known. The known resistance mechanisms include EGFR mutation or amplification, activation of other RTKs, such as AXL, HER2, insulin like growth factor 1 receptor (IGF1R) and MET, mutation of KRAS and PIK3CA, epithelial-mesenchymal transition (EMT), and transformation to small cell lung cancer (Leonetti et al., 2019; Santoni-Rugiu et al., 2019; Shi et al., 2022a; Wang et al., 2016; Westover et al., 2018). The key vulnerability of drug-resistant NSCLC cells is unknown.

Notably, a new class of EGFR TKIs, known as allosteric inhibitors, have shown promising preclinical activities against therapy-resistant EGFR mutants, including those with T790M and/or C797S mutations (Jia et al., 2016; De Clercq et al., 2019; Gero et al., 2022; Obst-Sander et al., 2022; To et al., 2022). Notably, C797S mutant is resistant to clinically available EGFR TKIs. There is evidence that allosteric EGFR inhibitors and other EGFR inhibitors bind to target cooperatively (Beyett et al., 2022). Studies have also shown that combining an allosteric EGFR inhibitor with osimertinib or cetuximab is more effective than any single agent (Jia et al., 2016; To et al., 2019; Obst-Sander et al., 2022). However, homodimerization or heterodimerization of EGFR mutants with HER family member confers resistance to allosteric EGFR inhibitors (To et al., 2019; 2022).

2. mAbs

Four EGFR mAbs have been approved for clinical use (Table 1), three of which are approved in the US, including cetuximab, panitumumab, and necitumumab. Cetuximab is approved for both CRC and HNSCC. Panitumumab is approved for CRC, and necitumumab is approved for squamous NSCLC. More than 80% of primary and metastatic CRCs are EGFR-positive, with overexpression in about 60% of the cases (Shia et al., 2005; Spano et al., 2005). EGFR mutation in CRC is uncommon, although several rare mutations in the ECD may prevent binding of cetuximab and/or panitumumab (Arena et al., 2015; Price et al., 2020). Both cetuximab and panitumumab bind to subdomain 3 of EGFR ECD to block EGFR activation by ligands (Li et al., 2005; Sickmier et al., 2016). Cetuximab is an IgG1 mAb and therefore can also activate ADCC (Kimura et al., 2007), whereas panitumumab is an IgG2 mAb and is incapable of eliciting ADCC. However, the two mAbs show similar efficacy in CRC patients (Price et al., 2014). Only about 10% of chemotherapy refractory patients respond to mAb monotherapy, and response (median progression-free survival) lasts about 1.5- 3.5 months, although combination with chemotherapy increases treatment response (Cunningham et al., 2004; Hecht et al., 2007; Saltz et al., 2004; Van Cutsem et al., 2007). Likewise, cetuximab monotherapy produces partial response in only 8-11% of HNSCC patients (Fury et al., 2012). Adding cetuximab to chemotherapy in HNSCC increases response rate from 20% to 36%, median progression-free survival from 3.3 to 5.6 months, and median overall survival from 7.4 to 10.1 months (Vermorken et al., 2008). Necitumumab is an IgG1 mAb and also inhibits EGFR by binding to subdomain 3 of its ECD (Li et al., 2008). It is active in squamous carcinoma but not adenocarcinoma in NSCLC, at least partly because EGFR mutation rate is very low in the former (2.1-4.5%) (Cheung et al., 2020; Joshi et al., 2017) and EGFR overexpression is more common in squamous NSCLC (82%) than

in non-squamous NSCLC (40%) (Hirsch et al., 2003). However, even in squamous NSCLC, necitumumab efficacy is very limited. Adding necitumumab to chemotherapy increased median overall survival only from 9.9 to 11.5 months (Thatcher et al., 2015). Nimotuzumab is an IgG1 mAb and also binds to subdomain 3 of EGFR ECD (Talavera et al., 2009), which has not been approved in the US. In a randomized phase 2 trial in NSCLC patients in India, complete response and partial response were 3.6% and 50% in nimotuzumab plus chemotherapy, respectively, and 4% and 30.9% in the chemotherapy control, respectively (Babu et al., 2014). Nimotuzumab did not significantly impact median progression-free survival or overall survival. As with EGFR TKIs, the mechanisms that confer primary and acquired resistance to the EGFR mAbs, which were uncovered mainly from studies in CRC, are complex and not fully known. The known resistance mechanisms include activating mutations of KRAS, NRAS, BRAF and PIK3CA, loss of PTEN, activation of VEGFR1 and IGF1R, amplification of HER2 and MET, mutation or methylation of EGFR, overexpression of EGFR ligand, and EMT (Bardelli and Siena, 2010; Park et al., 2022; Van Emburgh et al., 2014; Zhou et al., 2021). The key vulnerability of drug-resistant NSCLC cells is unknown.

3. CIMAvax

CIMAvax is currently undergoing clinical evaluation in the US in NSCLC patients, and its therapeutic efficacy has not been reported yet. A previous phase 3 trial in NSCLC patients in Cuba showed that CIMAvax induces anti-EGF antibodies and decreases serum EGF level, as expected, but only increases median survival time from 8.86 months in the control arm to 10.83 months in the vaccine arm (Rodriguez et al., 2016). The limited efficacy is not surprising,

however, because other EGFR ligands may compensate for EGF loss (Figure 1), and activating mutation of EGFR may render it independent of EGF or other ligands.

V. SUSTAINED EGFR OVEREXPRESSION AND EGFR CROSSTALK WITH OTHER RTKS TO COUNTER EGFR INHIBITORS

1. Lack of Downregulation of EGFR and Its mutants Confers Resistance to EGFR

Inhibitors

In cancer cells that overexpress WT or mutated EGFR, the expression level of the proteins often remains high when treated by EGFR TKIs or after developing resistance to these agents, while its auto-phosphorylation may be inhibited (Jacobsen et al., 2017; Liu et al., 2018; Shaurova et al., 2020; Tabara et al., 2012; Thomas et al., 2019; Wood et al., 2004). Shtiegman et al. reported that EGFR mutants that are associated with NSCLC, such as L858R/T790M, may dimerize with HER2 to evade ubiquitination and subsequent degradation (Shtiegman et al., 2007). Menard et al. showed that reactivation of lysosomal degradation of mutant EGFR in NSCLC cells, including L858R/T790M and other mutants, by inhibiting clathrin overcomes resistance to EGFR TKIs (Menard et al., 2018). An EGFR degrader known as DPBA (a 23-hydroxybetulinic acid derivative) is more effective than EGFR TKIs, including gefitinib, afatinib, and osimertinib, in inhibiting the growth of NSCLC cells expressing WT or mutated EGFR (Yao et al., 2020). Targeted degradation of EGFR and HER2 by proteolysis targeting chimera (PROTAC) is also more effective in inhibiting cancer cell growth than inhibiting the kinase activity of the RTKs (Burslem et al., 2018). Failure to downregulate EGFR by mAbs may also be a critical cause for resistance to these agents. Pre-treatment tumor EGFR level does not correlate with clinical response to cetuximab and panitumumab in CRC (Cunningham et al., 2004; Hecht et al., 2010).

However, EGFR downregulation after treatment with each mAb predicts the antitumor effect (Okada et al., 2017). In the majority of cultured cell lines and mouse tumor models that are either sensitive or resistant to cetuximab, panitumumab, or necitumumab, the mAbs are incapable of downregulating EGFR or even increasing its expression as well as increasing the expression of its family members, while its tyrosine phosphorylation may be inhibited (Ashraf et al., 2012; Bagchi et al., 2018; Iida et al., 2014; Iida et al., 2013; Misale et al., 2012; Ohnishi et al., 2015; Troiani et al., 2014; Wheeler et al., 2008; Yang et al., 2022). However, in cell lines and tumors where cetuximab downregulates EGFR or its mutants, it invariably inhibits the growth of these cells and tumors, whether they express WT or mutated EGFR (Perez-Torres et al., 2006; Yang et al., 2022). Also, downregulation of EGFR by siRNA or targeted degradation of EGFR by PEPD^{G278D}, a recombinant human protein which will be discussed later in detail, inhibits CRC cells that are resistant to cetuximab and panitumumab (Yang et al., 2022). It is poorly understood as to why EGFR mAbs downregulate EGFR in some cancer cells but not in most other cancer cells. Wheeler et al. showed that EGFR insensitivity to cetuximab may result from dysregulation of EGFR internalization and degradation involving CBL, an E3 ligase (Wheeler et al., 2008). Liao et al. showed that EGFR methylation in its ECD renders it less sensitive to cetuximab (Liao et al., 2015). Several rare acquired mutations in the ECD of EGFR were reported in CRC patients following cetuximab treatment, including R451C, K467T, and S492R, each of which prevents cetuximab binding and confers resistance to cetuximab (Arena et al., 2015; Price et al., 2020). The R451C and K467T mutants also bind poorly to panitumumab (Arena et al., 2015).

2. Heterodimerization of EGFR and Its Mutants with Other RTKs Confers Resistance to EGFR Inhibitors

EGFR is well known to heterodimerize with all its family members, including HER2, HER3 and HER4 (Okines et al., 2011). It also heterodimerizes with other RTKs, including AXL, IGF1R, MET, fibroblast growth factor receptor 2 (FGFR2), MER receptor tyrosine kinase (MERTK), platelet derived growth factor receptor α (PDGFRA), PDGF β (PDGFRB), and RET (Figure 2) (Chakravarty et al., 2017; Chang et al., 2015; Morgillo et al., 2006; Ortiz-Zapater et al., 2017; Taniguchi et al., 2019; Tanizaki et al., 2011; Wang et al., 2015; Yan et al., 2022). AXL, HER2, IGF1R, MERTK, MET, and RET fusion have been shown to confer resistance to EGFR TKIs in NSCLC (Marrocco et al., 2021; Piotrowska et al., 2018; Taniguchi et al., 2019; Yan et al., 2022; Yeo et al., 2015; Yonesaka et al., 2011; Zhu et al., 2021a). More information about EGFR heterodimerization may be found in a previous review (Kennedy et al., 2016). HER2 has also been shown to heterodimerize with a variety of RTKs (Kennedy et al., 2019). The RTKs mentioned above likely render cancer cells resistant to EGFR inhibitors at least in part by forming heterodimeric signaling units with EGFR, to allow EGFR to continue to exert oncogenic activities despite suppression of its tyrosine kinase. This property is not unique to EGFR, as HER3 is kinase-defective but exerts strong oncogenic activity by heterodimerizing with other RTKs as described before. Moreover, HER2, HER3 and PDGFRB have been shown to inhibit EGFR endocytosis by heterodimerizing with it (Wang et al., 2015; Wang et al., 1999). Thomas et al. showed that EGFR TKIs, including gefitinib, erlotinib, and AEE728, stimulate EGFR dimerization, that EGFR TKI-inhibited EGFR is still required for the survival of EGFR-expressing cancer cells, and that downregulation of EGFR by siRNA or herdegradin (a peptide) kills TKI-resistant cells (Thomas et al., 2019). In NSCLC cells which harbor EGFR Exon19del (E746-A750del), EGFR TKI osimertinib stimulates AXL and increases AXL association with the EGFR mutant (Taniguchi et al., 2019). EGFR E746-A750del also heterodimerizes with

HER2 and HER3 in NSCLC cells (Sakai et al., 2007). Using computation methods, Zhu et al. found that there is a looser EGFR crosstalk with MET, HER2, and IGF1R for the drug-sensitive EGFR mutant (L858R) than for the drug-resistant mutant (L858R/T790M) (Zhu et al., 2021b). Indeed, more MET binds to EGFR L858R/T790M than to EGFR L858R and WT EGFR (Ortiz-Zapater et al., 2017). In cancer cells that develop acquired resistance to cetuximab, there is also increased EGFR dimerization with HER2 and HER3 and activation of these RTKs (Wheeler et al., 2008). These findings strongly suggest that disrupting EGFR heterodimerization may be key to improving the efficacy of EGFR targeted therapies and also suggest that it may not be sufficient to disrupt just one type of EGFR heterodimer.

VI. EMERGING EGFR DEGRADERS AND THEIR THERAPEUTIC ACTIVITIES

EGFR exerts both kinase-dependent and -independent oncogenic activities, and various EGFR heterodimers may contribute to the kinase-independent activities of EGFR and confer drug resistance, as described before. Therefore, eliminating the physical presence of EGFR may be a much more effective therapeutic strategy than inhibiting its kinase activity. Many agents have been shown to induce EGFR degradation, including PROTACs, non-PROTAC small molecules, antibody combinations, and non-antibody proteins (Table 2). These agents have shown promising preclinical therapeutic activities. Some of the degraders may primarily target cell surface EGFR, but they may also abolish EGFR functions in other locations (exosome, endosome, mitochondria, and nucleus), as EGFR is transferred to these locations from cell surface membrane.

1. PROTACs

PROTAC works by linking a small molecule that binds to a target protein with a ligand for an E3 ligase and achieving target degradation via intracellular proteolysis by the ubiquitin-proteasome system. It has emerged as a promising new platform for cancer drug development. Many EGFR-directed PROTACs have been synthesized (Table 2) and evaluated in cultured cells, one of which was also evaluated in a mouse tumor model *in vivo*. Burslem et al. synthesized several PROTACs by conjugating an EGFR TKI to a ligand that binds to E3 ligase von Hippel-Lindau (VHL) (Burslem et al., 2018). Using lapatinib as the EGFR TKI which binds to both EGFR and HER2, they showed that the PROTAC induces the degradation of both RTKs and is more effective in inhibiting cell growth than the equivalent kinase inhibitor. Using gefitinib which binds to EGFR mutants, they showed that the PROTAC induces the degradation of EGFR mutants including Exon19del and L858R. Exon19del and L858R mutants as well as other EGFR kinase domain mutants described below are activating EGFR mutants that occur in NSCLC. Using afatinib, they showed that the PROTAC induces the degradation of gefitinib-resistant EGFR^{L858R+T790M}. Zhang et al. synthesized a PROTAC that specifically targets EGFR^{L858R/T790M} by conjugating an experimental EGFR^{L858R/T790M}-specific inhibitor to a ligand that binds to VHL and showed that it induces the degradation of EGFR^{L858R/T790M} but not WT EGFR (Zhang et al., 2020b). Zhao et al. showed that a PROTAC that links an experimental EGFR TKI, 9-cyclopentyl-8-phenylamino-2-(4-(piperazin-1-yl)phenylamino)-9H-purine, to a ligand for VHL is highly effective against EGFR^{Exon19del} and EGFR^{L858R+T790M} but not WT EGFR (Zhao et al., 2020). Several other PROTACs, linking a novel EGFR TKI to a ligand for either VHL or cereblon, another E3 ligase, degrade EGFR^{Exon19del} but have weak activity against EGFR^{L858R+T790M} and WT EGFR (Zhang et al., 2020a). He et al. generated a PROTAC by conjugating osimertinib to a ligand for cereblon, which significantly decreases the expression of

EGFR^{Exon19del} and EGFR^{L858R+T790M} (He et al., 2020). Cheng et al. generated PROTACs by conjugating a gefitinib derivative to a ligand for either VHL or cereblon and showed that the PROTACs potently induce the degradation of EGFR^{Exon19del} and EGFR^{L858R} but not WT EGFR (Cheng et al., 2020; Yu et al., 2022). Qu et al. synthesized PROTACs by conjugating canertinib, an experimental EGFR TKI or a derivative of it to a ligand for cereblon and showed that these agents degrade EGFR^{L858R+T790M} and EGFR^{Exon19del} but is inactive against EGFR^{Exon19del+T790M} and WT EGFR (Qu et al., 2021). Shi et al. synthesized PROTACs by conjugating dacomitinib to a ligand for cereblon or VHL and showed that these agents are highly effective against EGFR^{Exon19del} but not WT EGFR, one of which strongly inhibits the growth of NSCLC cell xenograft harboring EGFR^{Exon19del} in mice (Shi et al., 2022b). Jang et al. generated a PROTAC by conjugating an allosteric EGFR inhibitor to a ligand for cereblon and showed that it is effective against multiple EGFR mutants, including EGFR^{L858R+T790M}, EGFR^{L858R+T790M+C797S}, and EGFR^{L858R+T790M+C718Q}, but not WT EGFR (Jang et al., 2020). Zhang et al. showed that an allosteric EGFR inhibitor-derived VHL-recruiting degrader is effective against EGFR^{Exon19del+T790M+C797S} but is only weakly effective or not effective at all against WT EGFR, EGFR^{Exon19del}, EGFR^{L858R+T790M}, and EGFR^{L858R} (Zhang et al., 2022). These studies show the wide-spread interest in developing PROTACs targeting EGFR, its mutants and HER2 in cancer, and the promise of this approach. However, there is significant redundancy in generating PROTACs targeting EGFR mutants by different research groups, and it is unclear whether any agent will be effective against a broad spectrum of EGFR mutants occurring in NSCLC.

2. Non-PROTAC Small Molecules

Yao et al. found that a 23-hydroxybetulinic acid derivative, termed DPBA, is an EGFR degrader by screening over 700 natural compounds and their derivatives (Yao et al., 2020). DPBA induces the degradation of EGFR but not its family members including HER2, HER3 and HER4. It induces lysosomal degradation of both WT EGFR and mutants including E736-A750del and L858R+T790M by binding to their ECD and inducing clathrin-independent endocytosis, without inducing their dimerization. It inhibits the growth of cancer cells and tumors harboring WT EGFR, EGFR^{E736-A750del}, or EGFR^{L858R+T790M} in vitro and in vivo. Terzuoli et al. reported that hydroxytyrosol (HT), from olive oil, induces EGFR degradation by stimulating its ubiquitination and inhibiting the growth of EGFR-expressing cancer cells in vitro and in vivo (Terzuoli et al., 2016). HT does not appear to downregulate EGFR in normal cells and has not been evaluated against EGFR mutants. Iradyan et al. reported that several furfuryl derivatives of 4-allyl-5-[2-(4-alkoxyphenyl)-quinolin-4-yl]-4H-1,2,4-triazole-3-thiol (VM26 and analogs) inhibit EGFR phosphorylation and induce its internalization and degradation by binding to an allosteric site located in the vicinity of the catalytic pocket in the kinase domain of the receptor (Iradyan et al., 2019). Choi et al. reported that tephrosin, a natural rotenoid, inhibits the phosphorylation of EGFR, HER2 and HER3, induces the internalization and lysosomal degradation of the RTKs, and cause cell death (Choi et al., 2010).

3. Antibody Combinations

Sym004, a 1:1 mixture of two IgG1 antibodies binding to two non-overlapping epitopes in the ECD subdomain 3 of EGFR, induces rapid internalization and lysosomal degradation of the receptor, and is more effective than cetuximab and panitumumab in inhibiting tumor growth in vivo (Jones et al., 2020; Pedersen et al., 2010). Sym004 is also effective against cancer cells and

tumors that are resistant to cetuximab and show increased EGFR expression (Iida et al., 2013). Sym004 is also more effective than cetuximab in CRC PDX models but unexpectedly did not improve survival in a phase 2 randomized clinical trial in metastatic CRC with acquired resistance to anti-EGFR mAb (Montagut et al., 2018). It is not known if Sym004 downregulates tumor EGFR in patients. Jacobsen et al. generated a mixture of six antibodies, termed Pan-HER (Sym013), which simultaneously targets EGFR, HER2, and HER3, and showed that Sym013 induces the degradation of all three RTKs and inhibits the growth of cancer cells and tumors in mice, including those resistant to cetuximab and trastuzumab (an anti-HER2 mAb) (Iida et al., 2016; Jacobsen et al., 2015). Notably, HER2 amplification may occur in nearly 4% of patients with metastatic CRC (Dumbrava et al., 2019), and HER2 confers resistance to EGFR inhibition as mentioned before. However, a first-in-human trial showed significant toxicity of Sym013 and potential difficulty in achieving a tolerated regimen with adequate target saturation (Berlin et al., 2022).

4. Non-Antibody Proteins

Peptidase D (PEPD), also known as prolidase, is a widely-distributed dipeptidase important for collagen metabolism (Myara et al., 1984). Surprisingly, we found that, while the endogenous intracellular PEPD has no effect on EGFR and its family members, exogenous recombinant human PEPD induces the internalization and lysosomal degradation of both EGFR and HER2 by binding to their ECD (Yang et al., 2016; 2018; Yang et al., 2013; Yang et al., 2014). PEPD binds to ECD subdomain 2 in EGFR but ECD subdomain 3 in HER2 (Yang et al., 2016; Yang et al., 2014). PEPD does not bind to HER3 and HER4 (Yang et al., 2014). The finding that PEPD binds to HER2 at high affinity ($K_d = 7$ nM) (Yang et al., 2014) was unexpected, because it had been

widely believed that HER2 exists in a closed state and cannot be liganded, and no ligand had been previously identified. Crystallography studies showed that the structure of HER2 ECD resembles a ligand-activated conformation that is ready for dimerization (Cho et al., 2003; Garrett et al., 2003). PEPD also represents a novel class of EGFR ligands, as all other EGFR ligands are first synthesized as membrane proteins and harbor an EGF motif, but PEPD neither is a membrane protein nor carries an EGF motif. The binding affinity of PEPD is lower towards EGFR ($K_d = 17$ nM) than HER2 (Yang et al., 2016). The enzymatic activity of PEPD is not required for targeting EGFR and HER2 (Yang et al., 2013; 2014; 2015; 2016). Recombinant PEPD^{G278D}, which is enzymatically inactive, shows no difference from PEPD in targeting EGFR and HER2, but it is a more attractive antitumor agent than PEPD. PEPD^{G278D} may not interfere with the enzymatic function of endogenous PEPD, and PEPD, but not PEPD^{G278D}, increases HIF1 α growth signaling due to inhibition of its degradation by the products of PEPD enzymatic reaction (Surazynski et al., 2008; Yang et al., 2015). PEPD^{G278D} and PEPD have shown strong antitumor activities in preclinical models of EGFR- and/or HER2-overexpressing cancers (Yang et al., 2015; 2016; Yang et al., 2014). In models of HER2-positive breast cancer and EGFR-positive CRC, PEPD^{G278D} strongly inhibits the growth of cancer cells and tumors that are resistant to clinically used EGFR and HER2 inhibitors (Yang et al., 2022; Yang et al., 2019). PEPD^{G278D} and PEPD target EGFR and HER2 overexpressed in cancer cells but not the RTKs expressed low in normal cells (Yang et al., 2015; 2019). This apparently is due to their unique binding mode. PEPD^{G278D} as well as PEPD are homodimers, and each subunit binds to a monomer of EGFR or HER2 to form a tetra-complex (Yang et al., 2014; 2015; 2019), which requires the RTKs to be overexpressed on cell membrane. Furthermore, while PEPD^{G278D} binds to both EGFR and HER2, it does not bind to both RTKs simultaneously and disrupts EGFR-

HER2 heterodimers by forming a tetra-complex with each RTK (Yang et al., 2015). This may be due to PEPD^{G278D} binding to different locations in the ECD of the RTKs. Besides WT EGFR and HER2, PEPD^{G278D} also targets EGFR mutants that do not bind to cetuximab and panitumumab (Yang et al., 2022). It is possible that PEPD^{G278D} is also effective against a wide spectrum of EGFR and HER2 mutants that occur in NSCLC, since PEPD^{G278D} binds to the ECD of the RTKs but the mutations occur in the intracellular kinase domain.

VII. CONCLUDING REMARKS

EGFR drives cancer development and progression through both kinase-dependent and kinase-independent functions. EGFR inhibitors that are currently available in the clinic, including mAbs and TKIs, inhibit EGFR kinase without inhibiting or even promoting its kinase-independent functions. These inhibitors have shown clinical efficacy in only a few types of cancers, and even in these cancers, drug resistance is common and treatment efficacy is not durable. CIMAvax is also limited in its mechanism of action for inhibiting EGFR, as it indirectly inhibits EGFR tyrosine kinase by inducing EGF-neutralizing antibody, but other EGFR ligands may compensate for EGF loss. CIMAvax is not known to modulate the kinase-independent activity of EGFR, and available data show very limited clinical efficacy of this vaccine. There is accumulating evidence that the kinase-independent activities of EGFR must also be targeted in addition to inhibiting its tyrosine kinase activity, in order to achieve better therapeutic outcomes and minimize drug resistance. Targeting the degradation of EGFR is a promising strategy for simultaneously abolishing both kinase-dependent and -independent functions of the RTK. A number of new agents have shown promising preclinical activity in inducing EGFR degradation and inhibiting cancer cell growth. Some of the agents also induce the degradation of other EGFR family members, which likely enhances the therapeutic efficacy. It will be important to confirm that the

target is overexpressed in cancer cells before use of such agent. Tumor heterogeneity undoubtedly presents challenge to any targeted therapy, and further research is needed to determine the therapeutic efficacy of targeted degradation of EGFR and its family members in tumors which carry other drug resistance drivers. Notably, we showed that KRAS mutation (G12D or G13D), BRAF mutation (V600E), and/or PIK3CA mutation (P449T or H1047R) do not confer resistance of CRC cells and tumors to PEPD^{G278D} which induces the degradation of both EGFR and HER2 (Yang et al., 2022). It is also important to evaluate whether combination of an EGFR degrader with other antitumor agents enhances treatment efficacy.

VIII. ACKNOWLEDGMENT

We thank Dr. Boyko Atanasov, Roswell Park Comprehensive Cancer Center, for reading the manuscript and suggesting improvements.

IX. DATA AVAILABILITY

The author declares that all the data supporting the findings are contained within the paper.

X. AUTHORSHIP CONTRIBUTION

Wrote the manuscript: Zhang, Y.

XI. REFERENCES

Abourehab MAS, Alqahtani AM, Youssif BGM and Gouda AM (2021) Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. *Molecules* **26**:6677.

Al-Akhrass H, Naves T, Vincent F, Magnaudeix A, Durand K, Bertin F, Melloni B, Jauberteau MO and Lalloue F (2017) Sortilin limits EGFR signaling by promoting its internalization in lung cancer. *Nat Commun* **8**:1182.

Al-Nedawi K, Meehan B, Kerbel RS, Allison AC and Rak J (2009) Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. *Proc Natl Acad Sci U S A* **106**:3794-3799.

Ali A, Levantini E, Teo JT, Goggi J, Clohessy JG, Wu CS, Chen L, Yang H, Krishnan I, Kocher O, Zhang J, Soo RA, Bhakoo K, Chin TM and Tenen DG (2018) Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. *EMBO Mol Med* **10**:e8813

An Z, Aksoy O, Zheng T, Fan QW and Weiss WA (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. *Oncogene* **37**:1561-1575.

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A and Montagut C (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. *Clin Cancer Res* **21**:2157-2166.

Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ and Bodmer WF (2012) Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. *Proc Natl Acad Sci U S A* **109**:21046-21051.

- Babu KG, Prabhash K, Vaid AK, Sirohi B, Diwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, Raina V and Mohan R (2014) Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. *Onco Targets Ther* **7**:1051-1060.
- Bagchi A, Haidar JN, Eastman SW, Vieth M, Topper M, Iacolina MD, Walker JM, Forest A, Shen Y, Novosiadly RD and Ferguson KM (2018) Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance. *Mol Cancer Ther* **17**:521-531.
- Bardelli A and Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* **28**:1254-1261.
- Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH and Muraro R (2004) Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. *J Pathol* **204**:317-325.
- Beji A, Horst D, Engel J, Kirchner T and Ullrich A (2012) Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. *Clin Cancer Res* **18**:956-968.
- Berlin J, Tolcher AW, Ding C, Whisenant JG, Horak ID, Wood DL, Nadler PI, Hansen UH, Lantto J, Skartved NJO, Pedersen MW and Patnaik A (2022) First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. *Invest New Drugs* **40**:586-595.

Bertotti A and Sassi F (2015) Molecular pathways: sensitivity and resistance to anti-EGFR antibodies. *Clin Cancer Res* **21**:3377-3383.

Beyett TS, To C, Heppner DE, Rana JK, Schmoker AM, Jang J, De Clercq DJH, Gomez G, Scott DA, Gray NS, Jänne PA and Eck MJ (2022) Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. *Nat Commun* **13**:2530.

Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. *J Biol Chem* **274**:8335-8343.

Bollu LR, Katreddy RR, Blessing AM, Pham N, Zheng B, Wu X and Weihua Z (2015) Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation. *Oncotarget* **6**:34992-35003.

Brand TM, Iida M, Li C and Wheeler DL (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. *Discov Med* **12**:419-432.

Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J, Crew AP, Hines J and Crews CM (2018) The advantages of targeted protein degradation over inhibition: an RTK case study. *Cell Chem Biol* **25**:67-77.

Byeon SJ, Lee HS, Kim MA, Lee BL and Kim WH (2017) Expression of the ERBB family of ligands and receptors in gastric cancer. *Pathobiology* **84**:210-217.

Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, Peng XC, Xiang Y, Ma Z, Cui SZ and Xin HW (2020) The latest battles between EGFR monoclonal antibodies and resistant tumor cells. *Front Oncol* **10**:1249.

Caldieri G, Malabarba MG, Di Fiore PP and Sigismund S (2018) EGFR trafficking in physiology and cancer, in *Endocytosis and Signaling* (Lamaze C, and Prior I eds) pp 235-272, Springer International Publishing AG, Switzerland.

Carpenter G, King L, Jr. and Cohen S (1978) Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. *Nature* **276**:409-410.

Chakraborty S, Li L, Puliappadamba VT, Guo G, Hatanpaa KJ, Mickey B, Souza RF, Vo P, Herz J, Chen MR, Boothman DA, Pandita TK, Wang DH, Sen GC and Habib AA (2014) Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. *Nat Commun* **5**:5811.

Chakravarty D, Pedraza AM, Cotari J, Liu AH, Punko D, Kokroo A, Huse JT, Altan-Bonnet G and Brennan CW (2017) EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. *Sci Rep* **7**:9043.

Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, Li W and Li J (2015) Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. *Oncotarget* **6**:2009-2022.

Che TF, Lin CW, Wu YY, Chen YJ, Han CL, Chang YL, Wu CT, Hsiao TH, Hong TM and Yang PC (2015) Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. *Oncotarget* **6**:37349-37366.

Cheng M, Yu X, Lu K, Xie L, Wang L, Meng F, Han X, Chen X, Liu J, Xiong Y and Jin J (2020) Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders. *J Med Chem* **63**:1216-1232.

- Cheung AH, Tong JH, Chung LY, Chau SL, Ng CS, Wan IYP and To KF (2020) EGFR mutation exists in squamous cell lung carcinoma. *Pathology* **52**:323-328.
- Chew HY, De Lima PO, Gonzalez Cruz JL, Banushi B, Echejoh G, Hu L, Joseph SR, Lum B, Rae J, O'Donnell JS, de Long LM, Okano S, King B, Barry R, Moi D, Mazzieri R, Thomas R, Souza-Fonseca-Guimaraes F, Foote M, McCluskey A, Robinson PJ, Frazer IH, Saunders NA, Parton RG, Dolcetti R, Cuff K, Martin JH, Panizza B, Walpole E, Wells JW and Simpson F (2020) Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. *Cell* **180**:895-914.
- Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr. and Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature* **421**:756-760.
- Choi S, Choi Y, Dat NT, Hwangbo C, Lee JJ and Lee JH (2010) Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. *Cancer Lett* **293**:23-30.
- Chung CH, Zhang Q, Hammond EM, Trotti AM, 3rd, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH and Ang KK (2011) Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* **81**:331-338.
- Clark AJ, Ishii S, Richert N, Merlino GT and Pastan I (1985) Epidermal growth factor regulates the expression of its own receptor. *Proc Natl Acad Sci U S A* **82**:8374-8378.
- Coker KJ, Staros JV and Guyer CA (1994) A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. *Proc Natl Acad Sci U S A* **91**:6967-6971.

- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* **351**:337-345.
- De Clercq, DJH, Heppner DE, To C, Jang J, Park E, Yun C-H, Mushajiang M, Shin BH, Gero TW, Scott DA, Jänne PA, Eck MJ and Gray NS (2019) Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors. *ACS Med Chem Lett* **10**:1549-1553.
- de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Doooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L and CodeBreaK 200 Investigators (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. *Lancet* **401**:733-746.
- Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, Huttemann M, Douglas R, Haddad G and Parsons SJ (2009) Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. *J Biol Chem* **284**:36592-36604.
- Dhillon S (2021) Lazertinib: first approval. *Drugs* **81**:1107-1173.
- Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA and Meric-Bernstam F (2019) Targeting

ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. *JCO Precis Oncol* **3**:PO.18.00345.

Eldredge ER, Korf GM, Christensen TA, Connolly DC, Getz MJ and Maihle NJ (1994)

Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. *Mol Cell Biol* **14**:7527-7534.

Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, Mesa C, Luaces PL, Santos-Morales

O, Groman A, Cedeno C, Cinquino A, Fisher DT, Puzanov I, Opyrchal M, Fountzilas C, Dai T, Ernstoff M, Attwood K, Hutson A, Johnson C, Mazorra Z, Saavedra D, Leon K, Lage A, Crombet T and Dy GK (2022) Augmenting antibody response to EGF-depleting immunotherapy: findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. *Front Oncol* **12**:958043.

Ewald JA, Wilkinson JC, Guyer CA and Staros JV (2003) Ligand- and kinase activity-

independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. *Exp Cell Res* **282**:121-131.

Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW,

Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA,

Henry H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H and Price TJ (2022)

Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation

(CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. *Lancet Oncol* **23**:115-124.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R,

Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H,

- Haque S and Pfister DG (2012) A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m² for patients with recurrent or metastatic head and neck squamous cell cancer. *J Natl Compr Canc Netw* **10**:1391-1398.
- Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F and Ferraraccio F (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. *World J Surg* **31**:1458-1468.
- Gan HK, Cvrljevic AN and Johns TG (2013) The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. *FEBS J* **280**:5350-5370.
- Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW and Ward CW (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. *Mol Cell* **11**:495-505.
- Gero TW, Heppner DE, Beyett TS, To C, Azevedo SC, Jang J, Bunnell T, Feru F, Li Z, Shin BH, Soroko KM, Gokhale PC, Gray NS, Jänne PA, Eck MJ and Scott DA (2022) Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. *Bioorg Med Chem Lett* **68**:128718.
- Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, Marinello P, Guillen G and Lage A (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. *Ann Oncol* **9**:431-435.
- Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T,

- Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X and Rivera VM (2021) Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. *Cancer Discov* **11**:1672-1687.
- Hajdu T, Varadi T, Rebenku I, Kovacs T, Szollosi J and Nagy P (2020) Comprehensive model for epidermal growth factor receptor ligand binding involving conformational states of the extracellular and the kinase domains. *Front Cell Dev Biol* **8**:776.
- Han H, Li S, Chen T, Fitzgerald M, Liu S, Peng C, Tang KH, Cao S, Chouitar J, Wu J, Peng D, Deng J, Gao Z, Baker TE, Li F, Zhang H, Pan Y, Ding H, Hu H, Pyon V, Thakurdin C, Papadopoulos E, Tang S, Gonzalez F, Chen H, Rivera VM, Brake R, Vincent S and Wong KK (2021a) Targeting HER2 exon 20 insertion-mutant lung adenocarcinoma with a novel tyrosine kinase inhibitor mobocertinib. *Cancer Res* **81**:5311-5324.
- Han L, Zhang X, Wang Z, Zhang X, Zhao L, Fu W, Liang X, Zhang Z and Wang Y (2021b) SH-1028, an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. *Front Pharmacol* **12**:665253.
- He K, Zhang Z, Wang W, Zheng X, Wang X and Zhang X (2020) Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. *Bioorg Med Chem Lett* **30**:127167.
- Hecht JR, Mitchell E, Neubauer MA, Burris HA, 3rd, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J and Berlin J (2010) Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. *Clin Cancer Res* **16**:2205-2213.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG and Meropol NJ (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. *Cancer* **110**:980-988.

Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R and Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. *Clin Cancer Res* **11**:1462-1466.

Heppner DE, Wittlinger F, Beyett TS, Shaurova T, Urul DA, Buckley B, Pham CD, Schaeffner IK, Yang B, Ogboo BC, May EW, Schaefer EM, Eck MJ, Laufer SA and Hershberger PA (2022) Structural basis for inhibition of mutant EGFR with lazertinib (YH25448). *ACS Med Chem Lett* **13**:1856-1863.

Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C and Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. *J Clin Oncol* **21**:3798-3807.

Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F and Bardelli A (2014) TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. *Clin Cancer Res* **20**:6429-6438.

Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R and Li BT (2020) KRAS(G12C) inhibition with sotorasib in advanced solid tumors. *N Engl J Med* **383**:1207-1217.

Hong L, Han Y, Zhang H, Zhao Q, Yang J and Ahuja N (2013) High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis. *Genet Test Mol Biomarkers* **17**:348-351.

Hossam M, Lasheen DS and Abouzid KA (2016) Covalent EGFR inhibitors: binding mechanisms, synthetic approaches, and clinical profiles. *Arch Pharm (Weinheim)* **349**:573-593.

Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ and Wheeler DL (2016) Targeting the HER family with pan-HER effectively overcomes resistance to cetuximab. *Mol Cancer Ther* **15**:2175-2186.

Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R and Wheeler DL (2014) Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. *Mol Cancer* **13**:242.

Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M and Wheeler DL (2013) Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. *Neoplasia* **15**:1196-1206.

Iradyan M, Iradyan N, Hulin P, Hambardzumyan A, Gyulkhandanyan A, Alves de Sousa R, Hessani A, Roussakis C, Bollot G, Bauvais C and Sakanyan V (2019) Targeting degradation of EGFR through the allosteric site leads to cancer cell detachment-promoted death. *Cancers (Basel)* **11**:1094.

Jacobsen HJ, Poulsen TT, Dahlman A, Kjaer I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Pedersen MW, Kragh M and Lantto J (2015) Pan-HER, an

antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity. *Clin Cancer Res* **21**:4110-4122.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixido C, Karachaliou N, Pedersen MH, Castellvi J, Garzon M, Codony-Servat C, Codony-Servat J, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ and Rosell R (2017) Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. *Nat Commun* **8**:410.

Jang J, To C, De Clercq DJH, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, Janne PA and Gray NS (2020) Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations. *Angew Chem Int Ed Engl* **59**:14481-14489.

Jia Y, Yun C-H, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys P-Y, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong K-K, Janne PA and Eck MJ (2016) Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors. *Nature* **534**:129-132.

Jiang D, Li X, Wang H, Shi Y, Xu C, Lu S, Huang J, Xu Y, Zeng H, Su J, Hou Y and Tan L (2015) The prognostic value of EGFR overexpression and amplification in esophageal squamous cell carcinoma. *BMC Cancer* **15**:377.

Jones S, King PJ, Antonescu CN, Sugiyama MG, Bhamra A, Surinova S, Angelopoulos N, Kragh M, Pedersen MW, Hartley JA, Futter CE and Hochhauser D (2020) Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. *Sci Rep* **10**:663.

- Joshi A, Zanwar S, Noronha V, Patil VM, Chougule A, Kumar R, Janu A, Mahajan A, Kapoor A and Prabhash K (2017) EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? *Onco Targets Ther* **10**:1859-1863.
- Kancha RK, von Bubnoff N, Peschel C and Duyster J (2009) Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. *Clin Cancer Res* **15**:460-467.
- Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM and Kurzrock R (2019) Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: analysis of cell-free circulating tumor DNA in patients with advanced malignancies. *JCO Precis Oncol* **3**:PO.18.00180.
- Kempf E, Rousseau B, Besse B and Paz-Ares L (2016) KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. *Eur Respir Rev* **25**:71-76.
- Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W and Croucher DR (2019) Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. *Breast Cancer Res* **21**:43.
- Kennedy SP, Hastings JF, Han JZ and Croucher DR (2016) The under-appreciated promiscuity of the epidermal growth factor receptor family. *Front Cell Dev Biol* **4**:88.
- Kim B, Park YS, Sung JS, Lee JW, Lee SB and Kim YH (2021) Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer. *Cancer Med* **10**:372-385.

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T and Nishio K (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. *Cancer Sci* **98**:1275-1280.

Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K and Kirii Y (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. *Genes Cells* **18**:110-122.

Kudlow JE, Cheung CY and Bjorge JD (1986) Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line. *J Biol Chem* **261**:4134-4138.

Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, Pannicia C, Kurie JM and Threadgill DW (2009) Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. *J Clin Invest* **119**:2702-2713.

Lee HH, Wang YN and Hung MC (2015a) Non-canonical signaling mode of the epidermal growth factor receptor family. *Am J Cancer Res* **5**:2944-2958.

Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ and Park SY (2015b) Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. *Br J Cancer* **112**:103-111.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E and Tiseo M (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br J Cancer* **121**:725-737.

Li S, Kussie P and Ferguson KM (2008) Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. *Structure* **16**:216-227.

- Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P and Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. *Cancer Cell* **7**:301-311.
- Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S and Hung MC (2015) PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. *J Clin Invest* **125**:4529-4543.
- Liu C, Shaurova T, Shoemaker S, Petkovich M, Hershberger PA and Wu Y (2018) Tumor-targeted nanoparticles deliver a vitamin D-based drug payload for the treatment of EGFR tyrosine kinase inhibitor-resistant lung cancer. *Mol Pharm* **15**:3216-3226.
- Liu J, Xia X and Huang P (2020) xCT: a critical molecule that links cancer metabolism to redox signaling. *Mol Ther* **28**:2358-2366.
- Luetke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA and Lee DC (1994) The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. *Genes Dev* **8**:399-413.
- Lyu H, Han A, Polsdofer E, Liu S and Liu B (2018) Understanding the biology of HER3 receptor as a therapeutic target in human cancer. *Acta Pharm Sin B* **8**:503-510.
- Maiti GP, Mondal P, Mukherjee N, Ghosh A, Ghosh S, Dey S, Chakrabarty J, Roy A, Biswas J, Roychoudhury S and Panda CK (2013) Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. *PLoS One* **8**:e63440.

Marrocco I, Romaniello D, Vaknin I, Drago-Garcia D, Oren R, Uribe ML, Belugali Nataraj N,

Ghosh S, Eilam R, Salame TM, Lindzen M and Yarden Y (2021) Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.

EMBO Mol Med **13**:e13144.

Menard L, Floc'h N, Martin MJ and Cross DAE (2018) Reactivation of mutant-EGFR

degradation through clathrin inhibition overcomes resistance to EGFR tyrosine kinase inhibitors. *Cancer Res* **78**:3267-3279.

Midha A, Dearden S and McCormack R (2015) EGFR mutation incidence in non-small-cell lung

cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *Am J Cancer Res* **5**:2892-2911.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R,

Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D and Bardelli A (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Nature **486**:532-536.

Montagut C, Argiles G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted

T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sanchez-Martin FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A and Tabernero J (2018) Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and

- molecularly selected by circulating tumor DNA analyses: A phase 2 randomized clinical trial. *JAMA Oncol* **4**:e175245.
- Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. *Cancer Res* **66**:10100-10111.
- Myara I, Charpentier C and Lemonnier A (1984) Prolidase and prolidase deficiency. *Life Sci* **34**:1985-1998.
- Neal DE, Sharples L, Smith K, Fennelly J, Hall RR and Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. *Cancer* **65**:1619-1625.
- Obst-Sander U, Ricci A, Kuhn B, Friess T, Koldewey P, Kuglstatter A, Hewings D, Goergler A, Steiner S, Rueher D, Imhoff M-P, Raschetti N, Marty H-P, Dietzig A, Rynn C, Ehler A, Burger D, Kornacker M, Schaffland JP, Herting F, Pao W, Bischoff JR, Martoglio B, Nagel YA and Jaeschke G (2022) Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung cancer as a single agent or in combination with osimertinib. *J Med Chem* **65**:13052-13073.
- Ohnishi Y, Yasui H, Kakudo K and Nozaki M (2015) Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway. *Int J Oncol* **47**:2165-2172.
- Okada Y, Kimura T, Nakagawa T, Okamoto K, Fukuya A, Goji T, Fujimoto S, Sogabe M, Miyamoto H, Muguruma N, Tsuji Y, Okahisa T and Takayama T (2017) EGFR downregulation after anti-EGFR therapy predicts the antitumor effect in colorectal cancer. *Mol Cancer Res* **15**:1445-1454.

- Okines A, Cunningham D and Chau I (2011) Targeting the human EGFR family in esophagogastric cancer. *Nat Rev Clin Oncol* **8**:492-503.
- Olayioye MA, Neve RM, Lane HA and Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* **19**:3159-3167.
- Ortiz-Zapater E, Lee RW, Owen W, Weitsman G, Fruhwirth G, Dunn RG, Neat MJ, McCaughan F, Parker P, Ng T and Santis G (2017) MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mutations and altered by MET kinase inhibition. *PLoS One* **12**:e0170798.
- Pan PC and Magge RS (2020) Mechanisms of EGFR resistance in glioblastoma. *Int J Mol Sci* **21**:8471.
- Park YL, Kim HP, Ock CY, Min DW, Kang JK, Lim YJ, Song SH, Han SW and Kim TY (2022) EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. *Oncogene* **41**:2026-2038.
- Parseghian CM, Napolitano S, Loree JM and Kopetz S (2019) Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. *Clin Cancer Res* **25**:6899-6908.
- Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS and Kragh M (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. *Cancer Res* **70**:588-597.
- Perez-Torres M, Guix M, Gonzalez A and Arteaga CL (2006) Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. *J Biol Chem* **281**:40183-40192.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK,

Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB,

Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK,

Clifford C, Ou SI, Wolf B, Hata AN and Sequist LV (2018) Landscape of acquired

resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined

EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

Cancer Discov **8**:1529-1539.

Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, Ruff P, Satya Suresh A, Thomas A,

Tjulandin S and Peeters M (2020) Frequency of S492R mutations in the epidermal

growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal

cancer treated with panitumumab or cetuximab monotherapy. *Cancer Biol Ther* **21**:891-

898.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S,

Zhang K, Murugappan S and Sidhu R (2014) Panitumumab versus cetuximab in patients

with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer

(ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Lancet Oncol **15**:569-579.

Psyrrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL,

Rimm DL and Dimopoulos MA (2005) Effect of epidermal growth factor receptor

expression level on survival in patients with epithelial ovarian cancer. *Clin Cancer Res*

11:8637-8643.

Qu X, Liu H, Song X, Sun N, Zhong H, Qiu X, Yang X and Jiang B (2021) Effective

degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs

through both proteasome and autophagy/lysosome degradation systems. *Eur J Med Chem* **218**:113328.

Ramakrishnan MS, Eswaraiyah A, Crombet T, Piedra P, Saurez G, Iyer H and Arvind AS (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. *MAbs* **1**:41-48.

Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H and Sinicrope FA (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. *Br J Cancer* **102**:165-172.

Rodriguez PC, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodriguez G, Mazorra Z, Lage A, Crombet T and Neningen E (2016) A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. *Clin Cancer Res* **22**:3782-3790.

Rodriguez PC, Rodriguez G, Gonzalez G and Lage A (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. *MEDICC Rev* **12**:17-23.

Roskoski R, Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. *Pharmacol Res* **79**:34-74.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N and Nishio K (2007) Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. *Cancer Sci* **98**:1498-1503.

- Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J and Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol* **22**:1201-1208.
- Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ and Altevogt P (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. *J Cell Biochem* **103**:1783-1797.
- Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M and Sorensen JB (2019) Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. *Cancers (Basel)* **11**:923.
- Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS and Hershberger PA (2020) Vitamin D3 metabolites demonstrate prognostic value in EGFR-mutant lung adenocarcinoma and can be deployed to oppose acquired therapeutic resistance. *Cancers (Basel)* **12**:675.
- Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, Wang Y and Li W (2022a) Emerging strategies to overcome resistance to third-generation EGFR inhibitors. *J Hematol Oncol* **15**:94.
- Shi S, Du Y, Huang L, Cui J, Niu J, Xu Y and Zhu Q (2022b) Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. *Bioorg Chem* **120**:105605.
- Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, Gerald W and Chen B (2005) Epidermal growth factor receptor expression and

gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. *Mod Pathol* **18**:1350-1356.

Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, Benjamin S, Corso S, Gan J, Yosef RB, Giordano S and Yarden Y (2007) Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. *Oncogene* **26**:6968-6978.

Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M and Holcman M (2007) The epidermal growth factor receptor: from development to tumorigenesis. *Differentiation* **75**:770-787.

Sibilia M and Wagner EF (1995) Strain-dependent epithelial defects in mice lacking the EGF receptor. *Science* **269**:234-238.

Sickmier EA, Kurzeja RJ, Michelsen K, Vazir M, Yang E and Tasker AS (2016) The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance. *PLoS One* **11**:e0163366.

Sigismund S, Algisi V, Nappo G, Conte A, Pascolutti R, Cuomo A, Bonaldi T, Argenzio E, Verhoef LG, Maspero E, Bianchi F, Capuani F, Ciliberto A, Polo S and Di Fiore PP (2013) Threshold-controlled ubiquitination of the EGFR directs receptor fate. *EMBO J* **32**:2140-2157.

Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S and Di Fiore PP (2008) Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. *Dev Cell* **15**:209-219.

Sigismund S, Avanzato D and Lanzetti L (2018) Emerging functions of the EGFR in cancer. *Mol Oncol* **12**:3-20.

- Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP and Polo S (2005) Clathrin-independent endocytosis of ubiquitinated cargos. *Proc Natl Acad Sci U S A* **102**:2760-2765.
- Singh B, Carpenter G and Coffey RJ (2016) EGF receptor ligands: recent advances. *F1000Res* **5**.
- Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D and Wind P (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. *Ann Oncol* **16**:102-108.
- Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow K, Liu Y and Phang JM (2008) Extracellular matrix and HIF-1 signaling: the role of prolydase. *Int J Cancer* **122**:1435-1440.
- Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, Tahira T, Hayashi K, Arao T, Nishio K, Rosell R, Kuwano M and Ono M (2012) Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. *PLoS One* **7**:e41017.
- Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, Krenzel U and Moreno E (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. *Cancer Res* **69**:5851-5859.
- Tan X, Lambert PF, Rapraeger AC and Anderson RA (2016) Stress-induced EGFR trafficking: mechanisms, functions, and therapeutic implications. *Trends Cell Biol* **26**:352-366.

Tan X, Thapa N, Sun Y and Anderson RA (2015) A kinase-independent role for EGF receptor in autophagy initiation. *Cell* **160**:145-160.

Tanaka T, Zhou Y, Ozawa T, Okizono R, Banba A, Yamamura T, Oga E, Muraguchi A and Sakurai H (2018) Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation. *J Biol Chem* **293**:2288-2301.

Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K and Yano S (2019) AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. *Nat Commun* **10**:259.

Tanizaki J, Okamoto I, Sakai K and Nakagawa K (2011) Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. *Br J Cancer* **105**:807-813.

Tao RH and Maruyama IN (2008) All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. *J Cell Sci* **121**:3207-3217.

Terzuoli E, Giachetti A, Ziche M and Donnini S (2016) Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation. *Mol Nutr Food Res* **60**:519-529.

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Balint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA and SQUIRE Investigators (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine

and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol* **16**:763-774.

Thomas R, Srivastava S, Katreddy RR, Sobieski J and Weihua Z (2019) Kinase-inactivated EGFR is required for the survival of wild-type EGFR-expressing cancer cells treated with tyrosine kinase inhibitors. *Int J Mol Sci* **20**:2515.

Thomas R and Weihua Z (2019) Rethink of EGFR in cancer with its kinase independent function on board. *Front Oncol* **9**:800.

Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC and et al. (1995) Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. *Science* **269**:230-234.

Tian WJ, Huang ML, Qin QF, Chen Q, Fang K and Wang PL (2016) Prognostic impact of epidermal growth factor receptor overexpression in patients with cervical cancer: a meta-analysis. *PLoS One* **11**:e0158787.

To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong K-K, Eck MJ, Gray NS and Jänne PA (2019) Single and dual targeting of mutant EGFR with an allosteric inhibitor. *Cancer Discov* **9**:926-943.

To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS and Jänne P (2022) An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. *Nat Cancer* **3**:402-417.

- Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F and Martinelli E (2014) Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. *Clin Cancer Res* **20**:3775-3786.
- Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H and Nagano O (2016) The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). *Cancer Res* **76**:2954-2963.
- Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M and Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* **25**:1658-1664.
- Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S and Bardelli A (2014) Acquired resistance to EGFR-targeted therapies in colorectal cancer. *Mol Oncol* **8**:1084-1094.
- Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* **359**:1116-1127.

Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C and Reis RM

(2008) Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. *Anticancer Res* **28**:913-920.

Wang J, Wang B, Chu H and Yao Y (2016) Intrinsic resistance to EGFR tyrosine kinase

inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. *Onco Targets Ther* **9**:3711-3726.

Wang Q, Chen X and Wang Z (2015) Dimerization drives EGFR endocytosis through two sets of compatible endocytic codes. *J Cell Sci* **128**:935-950.

Wang YN, Yamaguchi H, Hsu JM and Hung MC (2010) Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. *Oncogene* **29**:3997-4006.

Wang Z, Zhang L, Yeung TK and Chen X (1999) Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. *Mol Biol Cell* **10**:1621-1636.

Wee P and Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers (Basel)* **9**:52.

Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. *Cancer Cell* **13**:385-393.

Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. *Ann Oncol* **29**:i10-i19.

- Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. *Oncogene* **27**:3944-3956.
- Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM and Shewchuk L (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. *Cancer Res* **64**:6652-6659.
- Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, Hirai H, Tushima T, Akanuma Y, Fujita T, Komuro I, Yazaki Y and Kadowaki T (1997) Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. *Nature* **390**:91-96.
- Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, Wang X, Frye SV, Behera M, Schneider F, Ramalingam SS, Owonikoko T, Earp HS, DeRyckere D and Graham DK (2022) MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. *J Clin Invest* **132**:e150517.
- Yang L, Bhattacharya A, Li Y, Sexton S, Ling X, Li F and Zhang Y (2022) Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. *J Exp Clin Cancer Res* **41**:184.
- Yang L, Li Y, Bhattacharya A and Zhang Y (2015) Inhibition of ERBB2-overexpressing tumors by recombinant human prolidase and its enzymatically inactive mutant. *EBioMedicine* **2**:396-405.

Yang L, Li Y, Bhattacharya A and Zhang Y (2016) Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. *Oncotarget* **7**:42340-42352.

Yang L, Li Y, Bhattacharya A and Zhang Y (2019) A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. *Sci Transl Med* **11**:eaav1620.

Yang L, Li Y, Ding Y, Choi KS, Kazim AL and Zhang Y (2013) Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. *J Biol Chem* **288**:2365-2375.

Yang L, Li Y and Zhang Y (2014) Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth. *Cell Death Dis* **5**:e1211.

Yao JJ, Zhang LL, Gao TS, Peng YL, Lawrence WR, Zhang WJ, Zhang F, Zhou GQ, Wang SY and Sun Y (2018) Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. *Cancer Biol Ther* **19**:1102-1107.

Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, Qi Q, Lu JJ, Fan CL, Chen MF, Qi M, Li XB, Hong J, Zhang DM and Ye WC (2020) Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. *Signal Transduct Target Ther* **5**:214.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY and Kim TJ (2015) Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-

small cell lung cancer patients harboring activating EGFR mutations. *Lung Cancer* **87**:311-317.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K and Janne PA (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci Transl Med* **3**:99ra86.

Yoshida K, Takanashi A, Kyo E, Ito M, Ito H, Niimoto M, Hattori T and Tahara E (1989) Epidermal growth factor induces the expression of its receptor gene in human gastric carcinoma cell line TMK-1. *Jpn J Cancer Res* **80**:743-746.

Yu X, Cheng M, Lu K, Shen Y, Zhong Y, Liu J, Xiong Y and Jin J (2022) Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras. *J Med Chem* **65**:8416-8443.

Yu X, Sharma KD, Takahashi T, Iwamoto R and Mekada E (2002) Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. *Mol Biol Cell* **13**:2547-2557.

Yun CW and Lee SH (2018) The roles of autophagy in cancer. *Int J Mol Sci* **19**:3466.

Zhang H, Xie R, Ai-Furas H, Li Y, Wu Q, Li J, Xu F and Xu T (2022) Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting Del19/T790M/C797S mutation. *ACS Med Chem Lett* **13**:278-283.

Zhang H, Zhao HY, Xi XX, Liu YJ, Xin M, Mao S, Zhang JJ, Lu AX and Zhang SQ (2020a)

Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). *Eur J Med Chem* **189**:112061.

Zhang X, Xu F, Tong L, Zhang T, Xie H, Lu X, Ren X and Ding K (2020b) Design and

synthesis of selective degraders of EGFR(L858R/T790M) mutant. *Eur J Med Chem* **192**:112199.

Zhao HY, Yang XY, Lei H, Xi XX, Lu SM, Zhang JJ, Xin M and Zhang SQ (2020) Discovery

of potent small molecule PROTACs targeting mutant EGFR. *Eur J Med Chem* **208**:112781.

Zhou J, Ji Q and Li Q (2021) Resistance to anti-EGFR therapies in metastatic colorectal cancer:

underlying mechanisms and reversal strategies. *J Exp Clin Cancer Res* **40**:328.

Zhu H, Cao X, Ali-Osman F, Keir S and Lo HW (2010) EGFR and EGFRvIII interact with

PUMA to inhibit mitochondrial translocation of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. *Cancer Lett* **294**:101-110.

Zhu K, Lv Z, Xiong J, Zheng H, Zhang S, Jin H, Yu L, Li Z, Zhang J, Li C and Liang P (2021a)

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts. *Aging (Albany NY)* **13**:6890-6903.

Zhu M, Wang DD and Yan H (2021b) Genotype-determined EGFR-RTK heterodimerization and

its effects on drug resistance in lung cancer treatment revealed by molecular dynamics simulations. *BMC Mol Cell Biol* **22**:34.

XII. FOOTNOTES

This work was supported in part by grants from the National Cancer Institute (R01CA215093, and R01CA244601), a VCU Massey Comprehensive Cancer Center Startup Fund, and the Harrigan, Haw, and Luck Families Chair in Cancer Research Endowment. No author has an actual or perceived conflict of interest with the contents of this article.

XIII. TABLES

Table 1: Clinically used EGFR inhibitors

Agent type	Agent	Effect on EGFR kinase	Cancer treatment	Reference
TKI	Brigatinib	Reversible inhibition of kinase	NSCLC	Abourehab et al., 2021; Dhillon, 2021; Gonzalez et al., 2021; Han et al., 2021a
	Elotinib		NSCLC	
	Gefitinib		NSCLC	
	Icotinib*		NSCLC	
	Lapatinib		HER2-positive breast cancer	
	Simotinib*		NSCLC	
	Vandetanib		Medullary thyroid cancer	
	Afatinib	Irreversible inhibition of kinase	NSCLC	
	Almonertinib*		NSCLC	
	Dacomitinib		NSCLC	
	Lazertinib*		NSCLC	
	Mobocertinib		NSCLC	
	Neratinib		HER2-positive breast cancer	
	Olmotinib*		NSCLC	
Osimertinib	NSCLC			
Pyrotinib	HER2-positive breast cancer			
mAb	Cetuximab	Inhibition of ligand activation of kinase	CRC, HNSCC	Ramakrishnan et al., 2009; Cai et al., 2020; Yao et al., 2018
	Panitumumab		CRC	
	Necitumumab		NSCLC	
	Nimotuzumab*		HNSCC, glioma, nasopharyngeal carcinoma	

*These drugs are approved for clinical use outside the US.

Table 2: Emerging degraders of EGFR and its family members

Agent class	Agent	Targets	References
PROTACs	Lapatinib-based	EGFR, HER2	Burslem et al., 2018
	Dacomitinib-based Novel TKI-based	EGFR ^{Exon19del}	Shi et al. 2022b Zhang et al., 2020a
	Gefitinib-based Gefitinib derivative-based	EGFR ^{Exon19del} , EGFR ^{L858R}	Burslem et al., 2018 Cheng et al., 2020 Yu et al., 2022
	Afatinib-based Novel TKI-based	EGFR ^{L858R+T790M}	Burslem et al., 2018 Zhang et al., 2020b
	Osimertinib-based Novel TKI-based	EGFR ^{Exon19del} , EGFR ^{L858R+T790M}	He et al., 2020 Qu et al., 2021 Zhao et al., 2020
	Novel TKI-based	EGFR ^{L858R+T790M} , EGFR ^{L858R+T790M+C797S} , EGFR ^{L858R+T790M+C718Q}	Jang et al., 2020
	Novel TKI-based	EGFR ^{Exon19del+T790M+C797S}	Zhang et al., 2022
Non-PROTAC small molecules	DPBA	EGFR, EGFR ^{E736-A750del} , EGFR ^{L858R+T790M}	Yao et al., 2020
	Hydroxytyrosol	EGFR	Terzuoli et al., 2016
	VM26 and analogs	EGFR	Iradyan et al., 2019
	Tephrosin	EGFR, HER2, HER3	Choi et al., 2010
Antibody combinations	Sym004	EGFR	Pedersen et al., 2010
	Sym013	EGFR, HER2, HER3	Jacobsen et al., 2015
Non-antibody proteins	PEPD, PEPD ^{G278D}	EGFR, HER2	Yang et al., 2014 Yang et al., 2015 Yang et al., 2016

Note: The EGFR mutants listed in this table occur in NSCLC.

XIV. FIGURE LEGENDS

Figure 1. EGFR signaling and trafficking, and the effects of EGFR inhibitors and CIMAvax.

EGFR is activated by seven ligands. EGFR may also be activated by overexpression, by heterodimerizing with other RTKs, or by JAK2, FAS, and SRC. Other RTKs may be activated by binding to EGFR. EGFR may also bind to and stimulate the activity of non-RTK membrane proteins such as SGLT1. Activation of EGFR and its binding partners initiate multiple growth signaling pathways, leading to cell proliferation and other changes. Activated EGFR may be internalized and delivered to lysosome for degradation, be recycled to cell membrane to maintain signaling, or exert growth signaling in endosome, mitochondria, nucleus and exosome. EGFR heterodimerization may prevent EGFR internalization. EGFR mAbs and TKIs as well as CIMAvas only partially inhibit the EGFR signaling network.

Figure 2. EGFR heterodimers that may render EGFR inhibitors ineffective.

Listed are RTKs and non-RTK membrane proteins that have been shown to heterodimerize with EGFR, most of which have been shown to confer resistance to EGFR inhibitors. The RTKs that bind to EGFR may transphosphorylate EGFR, thereby rendering EGFR mAbs ineffective, and may autophosphorylate themselves, thereby rendering EGFR TKIs ineffective. Notably, unlike other proteins that bind to EGFR to promote oncogenic signaling, sortilin binds to EGFR to inhibit its signaling by inducing its internalization, but sortilin may be downregulated in cancer cells. LAPTM4B binds to EGFR in the endosome.

Figure 1




Figure 2

